ReachMD

Children often present with nephrotic syndrome and are frequently steroid resistant by the time #FSGS is confirmed on biopsy. Learn why genetics and disease classification are increasingly important in guiding care: ow.ly/x7Im50ZnlNn #Nephrology

Tomorrow: Hear expert perspectives on applying biomarker findings to ovarian cancer treatment planning, sequencing therapies, and providing patient-centered care. Register now: ow.ly/RPQe50ZcQ95 #OncologyEducation #OvarianCancer #CancerCare

What role does genetic testing play in FSGS? Identifying genetically mediated disease can inform treatment decisions and reduce exposure to immunosuppression when it may not be appropriate. Explore the discussion: ow.ly/e5vN50YFHQF #FSGS #Nephrology #PrecisionMedicine #PatientCare

How is genetic testing reshaping our understanding of FSGS? Panels assessing 60+ podocyte-specific genes are helping to identify genetically mediated disease and may help avoid unnecessary immunosuppression. Learn more: ow.ly/YtxJ50ZiCcv #Nephrology #FSGS #GeneticTesting

Catch this broadcast on ovarian cancer care featuring expert discussion on biomarker-informed treatment in frontline maintenance and platinum-resistant settings. Just one week left to sign up! Register for the program here: ow.ly/V8Hx50ZcPTl #GynecologicOncology #OvarianCancer #CME

Explore key findings from a phase 3 clinical trial comparing two HER2-directed antibody-drug conjugate therapies in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant treatment: ow.ly/ybag50ZfSh4 #Oncology#MedicalEducation

Last chance to register: Join Dr. Konrad Klinghammer live as he explores evolving evidence in resectable, LA HNSCC. Register now: ow.ly/OmOf50ZeKnz #HNSCC #OncologyEducation #Immunotherapy

Join a leading German expert for an interactive webinar series examining the evolving role of perioperative immunotherapy in resectable, locally advanced HNSCC, with a focus on treatment sequencing, patient selection, and multidisciplinary coordination. Register here: ow.ly/3ESi50ZeKjr #HNSCC #Immunotherapy #Oncology #MedEd

Maladaptive FSGS presents ongoing challenges in management. Hear how emerging treatment approaches may have broader application across FSGS subtypes: ow.ly/K83i50YFHCv #KidneyDisease #FSGS #Nephrology #MedicalEducation

Biomarker-guided decision-making remains central to individualized ovarian cancer care. Join this broadcast for expert discussion on treatment selection, sequencing strategies, and adverse event management across the care continuum. Register now: ow.ly/xxui50ZcPII #OvarianCancer #Oncology #MedEd

Can emerging therapies extend beyond primary FSGS? Current data suggest a role in maladaptive FSGS, where clinical needs remain significant. Learn more in this expert discussion: ow.ly/1GCR50Zcqs7 #FSGS #Nephrology #PatientCare #KidneyHealth

Tomorrow: Join Dr. Marc Oliva live as he dives into clinical evidence, treatment sequencing, and multidisciplinary coordination in resectable, locally advanced head and neck squamous cell carcinoma. Register now: ow.ly/q7VK50Zb97n #HNSCC #OncologyEducation #Immunotherapy

Don't miss the remaining two dates for a live broadcast on treating early symptomatic Alzheimer's disease. Faculty discuss standardized processes for therapy initiation, ARIA risk mitigation, and MRI-based monitoring to support safe and consistent care. This is a Worldwide Webinar Series, with subtitles available in French, Spanish, German, and Portuguese! Wherever you're located, we have an opportunity for you to join: ow.ly/Yjip50Z4q2w #Alzheimers #MedicalEducation #LiveEvent

Join a leading Spanish expert for a live, interactive webinar series exploring how perioperative immunotherapy may shape evolving treatment strategies in resectable, locally advanced HNSCC. He'll cover patient selection, sequencing approaches, multidisciplinary care integration, and more. Register now: ow.ly/2XvR50Zb7Yb #HNSCC #Immunotherapy #Oncology #MedEd

How should adjuvant therapy be optimized for patients with HER2-positive early breast cancer who remain at high risk after neoadjuvant treatment? The phase 3 DESTINY-Breast05 trial compared T-DXd with T-DM1 and helped inform updated NCCN guidance. Explore the data in this video brief from ASCO 2026: ow.ly/5S0Z50ZabLN #ASCO2026 #Oncology #BreastCancer

How should treatment plans evolve for patients with HER2-positive early breast cancer who remain at high risk of recurrence after neoadjuvant therapy? Explore findings from the phase 3 DESTINY-Breast05 trial comparing T-DXd vs T-DM1 in patients with residual invasive disease: ow.ly/CXzt50Z9G3g #Oncology

In case you missed it: a live event exploring treatment options for early symptomatic Alzheimer’s disease. Learn about streamlined referral thresholds, eligibility triage, and amyloid confirmation strategies. This Worldwide Webinar Series has subtitles available in French, German, Spanish, and Portuguese. Wherever you're located, there's a broadcast available. Register now: ow.ly/jh8N50Z4pUs #Alzheimers #MedicalEducation #LiveEvent

How might emerging therapies fit into FSGS management? Patients with persistent proteinuria may benefit from alternatives to standard RAS blockade, particularly when long-term tolerability is a priority. Learn more: ow.ly/hQBS50YFHtN #FSGS #Nephrology #PatientCare #KidneyHealth

Tomorrow: Join Dr. Christophe Le Tourneau live as he examines perioperative immunotherapy strategies in resectable LA HNSCC through clinical evidence and case discussions. Register now: ow.ly/icH450Z6q5S #HNSCC #OncologyEducation #Immunotherapy

Which patients may benefit most from emerging FSGS therapies? Those with persistent or nephrotic-range proteinuria remain at highest risk and may see meaningful reductions in proteinuria. Explore the clinical considerations: ow.ly/QB3a50Z6GEn #Nephrology #FSGS